EUVIMEDEUVIMED entdecken
Crossref

Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis

Youyi Wu, Tingting Chen, Songsong Wu, Yiwei Huang, Fuyao Li iD

Fundamental & Clinical Pharmacology · 2025-02 · 39 (1)

DOI: 10.1111/fcp.13044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 03.01.2025. Verfasst von Youyi Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department Oncology Radiotherapy, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People Hospital, Zhejiang, China. Hauptthemen laut MEDLINE: Oxaliplatin, Ferroptosis, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The development of resistance to oxaliplatin is a multifaceted process, often involving modifications in drug transport, DNA repair mechanisms, and the ability of cells to evade drug‐induced apoptosis.

Objective

To evaluate whether knocking down RFC3 promotes the sensitivity of colorectal cancer (CRC) cells to oxaliplatin, potentially offering a new approach to combat drug resistance. Methods siRNA‐mediated knockdown of RFC3 was employed in colorectal cancer cell lines to assess the impact on oxaliplatin responsiveness. Cell viability assays, clonogenic survival assays, and flow cytometry were conducted to evaluate the effects on cell growth and apoptosis. Additionally, immunoblot analysis was used to scrutinize modifications in the expression of pivotal protein expression in the Wnt/β‐catenin/GPX4 axis.

Results

RFC3 is highly expressed in CRC tissues and associated with prognosis. Knocking down RFC3 enhances the sensitivity of CRC cells to oxaliplatin. Additionally, the reduction of RFC3 promotes the susceptibility of chemoresistant tumor cells to oxaliplatin by inducing ferroptosis. Furthermore, the knockdown of RFC3 disrupts the Wnt/β‐catenin/GPX4 axis.

Conclusion

Depletion of RFC3 enhances the sensitivity of CRC cells to oxaliplatin via inducing ferroptosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinFerroptosisDrug Resistance, NeoplasmAntineoplastic AgentsReplication Protein CHumansCell Line, TumorGene Knockdown TechniquesColonic NeoplasmsCell SurvivalWnt Signaling PathwayApoptosisColorectal NeoplasmsCell Proliferation

Stichwörter der Autor:innen

FerroptosisRFC3Wnt/β‐catenin/GPX4colorectal cancer (CRC)oxaliplatin

Substanzen

OxaliplatinAntineoplastic AgentsReplication Protein C

Autor:innen und Institutionen

  • Department Oncology Radiotherapy, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People Hospital, Zhejiang, China.

ORCID-Profile: Fuyao Li

Zitieren

APA

Wu, Y., Chen, T., Wu, S., Huang, Y., & Li, F. (2025). Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis. Fundamental & Clinical Pharmacology, 39(1). https://doi.org/10.1111/fcp.13044

Vancouver

Wu Y, Chen T, Wu S, Huang Y, Li F. Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis. Fundamental & Clinical Pharmacology. 2025;39(1). doi:10.1111/fcp.13044

BibTeX
@article{Wu2025,
  author = {Wu, Youyi and Chen, Tingting and Wu, Songsong and Huang, Yiwei and Li, Fuyao},
  title = {Knockdown of RFC3 enhances the sensitivity of colon cancer cells to oxaliplatin by inducing ferroptosis},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  volume = {39},
  number = {1},
  doi = {10.1111/fcp.13044}
}
Kostenlos starten →